Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

NF1: early-phase trial registry

3 of 7 indexed NF1 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

NF1: 7 US clinical trials tracked, 3 recruiting.

NF1 is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 2 of these trials.

Enrollment posture brief

Registry condition nf1

OPEN 3 | RECR 43% | LATE 0 | EARLY 7 | RANK #2497 | SPON 2

Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%NF1 (this)43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near NF1

NF1 lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for NF1 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. NF1 is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates NF1 research.

    Johns Hopkins University accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most NF1 trials plan to enrol fewer than 100 people.

    Median target enrolment is 45 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.

  4. NF1 research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 22

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2

Named interventions

Most-linked intervention names on NF1 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Other Academic "sham" tutoring Behavioral
1 trials
reading tutoring intervention Behavioral
1 trials
FCN-159 Drug
1 trials
AZD6244 Drug
1 trials
Imlygic Drug
1 trials
Lovastatin Drug
1 trials
Placebo Oral Tablet Drug
1 trials
Mirdametinib Drug
1 trials

US sites by state

Facility locations filed on NF1 trials. A trial with sites in several states counts in each.

Maryland 4 trials
Pennsylvania 2 trials
Ohio 2 trials
New York 2 trials
California 2 trials
Utah 1 trials
Tennessee 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this NF1 page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NF1 condition card totals 7 registered trials; most-linked intervention Other Academic "sham" tutoring; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.